Dr. Reddy's Laboratories FY24 Annual Earnings Summary

Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.

US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.

FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.

US FDA issued a complete response letter for biosimilar Rituximab due to CMC questions; resolution expected around September, but timeline for approval remains uncertain.

Russia business grew 77% but on a low base; currency and geopolitical risks remain high.

Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.

Current lower price erosion may be temporary; management noted model hasn't changed, implying potential reversion.

Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.

Price erosion remains a headwind, though moderating. Management noted it fluctuates between high single-digit to low double-digit, impacting revenue growth.

Price erosion in US generics continues, though management describes it as stable. Any acceleration could pressure margins.

Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.

Management acknowledged price erosion on select large products, partially offset by other products. Continued erosion could pressure US margins.